Momenta Appoints Biosimilars Unit President

Michael Franken, M.D. has been appointed president of Momenta Pharmaceuticals’ Biosimilars Business and will serve as a member of the executive committee. Dr. Franken will oversee the operational management of the company’s biosimilars program, including its collaboration with Baxter International Inc., strategic planning, P&L responsibility, and other supporting activities. Dr. Franken will report to Craig Wheeler, Momenta’s president and chief executive officer.
 
Dr. Franken previously served as senior vice president and chief business officer of Radius Health, where he was responsible for the company’s commercial, business development, and strategy functions for its Phase III bone anabolic medicine to treat osteoporosis. Prior to Radius, he served as vice president and general manager, Solid Organ Transplantation, at Genzyme. During his 10-year career at Genzyme, he also held senior positions in corporate development portfolio and general management.
 
“Momenta’s biosimilars business presents an attractive opportunity for growth,” said Mr. Wheeler. “Michael brings more than 17 years of broad experience to the company, including a valuable combination of operations skills, market expertise and business development. With this focus, we will better align our resources and expertise to create an even stronger collaboration with Baxter to advance this core business.”